Editorial
doi: 10.3350/cmh.2012.18.3.268.
Epub 2012 Sep 25.
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
- PMID: 23091806
- PMCID: PMC3467429
- DOI: 10.3350/cmh.2012.18.3.268
Item in Clipboard
Editorial
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
Clin Mol Hepatol.
2012 Sep.
No abstract available
Keywords: Chronic hepatitis C; Genotype 1; Ribavirin.
Conflict of interest statement
The authors have no conflicts to disclose.
Comment on
-
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.Clin Mol Hepatol. 2012 Sep;18(3):272-8. doi: 10.3350/cmh.2012.18.3.272. Epub 2012 Sep 25. Clin Mol Hepatol. 2012. PMID: 23091807 Free PMC article.
Similar articles
-
[Comparison of efficacy of peginterferon and ribavirin combination therapy for chronic hepatitis C among Korean, Caucasian and other Asians].Korean J Gastroenterol. 2012 Nov;60(5):273-4. doi: 10.4166/kjg.2012.60.5.273. Korean J Gastroenterol. 2012. PMID: 23311002 Korean. No abstract available.
-
Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.Rev Esp Enferm Dig. 2009 Oct;101(10):665-70. doi: 10.4321/s1130-01082009001000001. Rev Esp Enferm Dig. 2009. PMID: 19899934 English, Spanish. No abstract available.
-
Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?Clin Mol Hepatol. 2013 Mar;19(1):26-8. doi: 10.3350/cmh.2013.19.1.26. Epub 2013 Mar 25. Clin Mol Hepatol. 2013. PMID: 23593606 Free PMC article. No abstract available.
-
[Therapy of chronic Hepatitis C in 2008].MMW Fortschr Med. 2008 Mar 27;150(13):31-4. doi: 10.1007/BF03365407. MMW Fortschr Med. 2008. PMID: 18522354 Review. German. No abstract available.
-
Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.Curr Gastroenterol Rep. 2002 Feb;4(1):23-30. doi: 10.1007/s11894-002-0034-y. Curr Gastroenterol Rep. 2002. PMID: 11825538 Review.
References
-
- Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703–714. - PubMed
-
- Bodenheimer HC, Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26:473–477. - PubMed
-
- McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–1492. - PubMed
-
- Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet. 1998;352:1426–1432. - PubMed
-
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
